Pricing and Access of Our Innovative Medicines

2023

At AbbVie, we are driven by the potential for innovative medicines to have a remarkable impact on patients.

Our commitment to patients inspires a dedicated focus on science and innovation.

We address the world's pressing health challenges by combining our experience in pioneering scientific breakthroughs with a focus on pursuing the best ideas in science.

We also recognize that innovative treatments can only make a difference if patients can get the medicines that they and their providers choose. Innovation, pricing, and access must work in harmony, which is why we are committed to ensuring that patients who need our medicines can access them.
We price our medicines to reflect the value they bring to patients and their families, the health system and to society.

We also consider the affordability and accessibility of our medicines for a diverse set of stakeholders, including patients, providers, governments and other payers, as well as the long-term sustainability of our innovation and societal impact.

- **Affordability & Accessibility:** AbbVie has comprehensive programs that enable patients to access our medicines at prices they can afford.
- **Sustaining our Innovation & Patient Impact:** We also consider our ability to sustain innovation that addresses patients’ most serious health issues, now and in the future.

Our pricing governance ensures our decisions are executed in line with AbbVie’s pricing approach, including established processes and policies that guide our discounting practices.
Our Approach to Patient Access and Support

AbbVie ensures our science and medicines serve the people who need them most. Innovative treatments are most impactful when patients have choice, access, and the right guidance and support.

Given complex health care system dynamics around the world, we believe efforts to support patients are a shared responsibility. All stakeholders in the health system — including governments, regulatory bodies, payers, health care providers and pharmaceutical companies — must do their part to support patients in their health journeys. That’s why we actively engage in intentional efforts around the world to increase patient access and provide appropriate support after a patient has received our medicine.

How we reduce barriers to access and support patients

We believe in actively working to broaden access and increasing affordability for patients facing a variety of circumstances.

• **Global Reach:** AbbVie works with local governments and regulatory authorities to make our treatments available in 175 countries and in key therapeutic areas of immunology, oncology, neuroscience, eye care and in our aesthetics portfolio.

• **Out-of-Pocket Cost Assistance:** AbbVie offers several programs that reduce the out-of-pocket costs patients pay for our medicines, with each program tailored to meet the unique needs of patients within a given geography, disease area and payer context.

• **Medicine Donation Programs:** Through our medicine donation programs, we provide medicines for people who have no other means of accessing them. We have seven ongoing medicine donation partnerships with non-governmental organizations providing care in low-and middle-income countries (LMICs). We also support requests for medical donations for pediatric health, mental health and HIV/AIDS, and access to surgical care by donation of our general anesthesia treatment for use in free surgeries.

• **Other Charitable Donations:** We make donations to independent charitable foundations, which provide co-pay assistance to patients in need, regardless of whether their treatments are AbbVie medicines.

**Patient Assistance in the U.S.**

• For patients with commercial insurance in the U.S., we offer co-pay assistance regardless of income. In the U.S., our co-pay assistance program is used by more than 90% of commercially insured patients to lower their co-pays to $5-$10 per month.

• For under/uninsured patients in the U.S., we offer myAbbVie Assist, which provides free medicine to those in need. This program helps 99% of uninsured patients who seek assistance. The income eligibility requirement for myAbbVie Assist is 600% of the Federal Poverty Level (FPL). In 2022, myAbbVie Assist supported over 198,000 patients in the United States.

We believe in helping more patients access the medicine they need as soon as they need it.

Through our compassionate use programs, AbbVie provides access to investigational drugs prior to regulatory approval for patients, as determined on a case-by-case basis and implemented through programs subject to established regulatory pathways. Our compassionate use programs span a variety of medicines across oncology, immunology, neuroscience and other therapeutic areas.

Additionally, we recognize that during the launch of a new medicine, patients’ access may be delayed as payers evaluate evidence to make reimbursement decisions. We work with governments and payer organizations to pursue early access pathways for patients who need alternative therapies.
We believe in increasing clinical trial access for underserved communities.

We are committed to improving clinical research diversity by understanding the prevalence of a disease in diverse populations. This commitment supports our efforts to drive equitable trial access and enhanced trial experiences for underrepresented populations.

To ensure our clinical trials are inclusive and representative, we evaluate real-world datasets to analyze the diversity of race, ethnicity, age and sex of people living with the diseases we are studying. With health equity gaps in mind, we create tailored plans to design clinical research programs by assessing protocol inclusivity, leveraging community partnerships, expanding investigator education and training, enhancing site selection and developing targeted patient outreach and retention strategies.

We believe that the right support for patients along their treatment journeys makes a meaningful difference in people's lives.

We are committed to providing the appropriate guidance and support to patients along their treatment journey. We offer greater than 530 patient support programs worldwide for patients who have started treatment on AbbVie medicines - each program being tailored to country and disease-specific needs. With the goal of improving health outcomes, these programs support patients in a variety of ways by enabling care and support when it’s needed most.

Through our patient support resources and other support resources, we offer educational programs that empower patients, their families and caregivers with the knowledge and resources to understand their disease and be active participants in their health journeys. We also provide education and support through personalized interactions to help patients adjust to the use of their AbbVie medicine.

Our Dedication to Advancing the Standard of Care

Our innovation efforts center around the patient. We work to help people around the world by changing the way diseases are treated. We are dedicated to discovering and delivering medicines and products to enhance lives today and address the medical challenges of tomorrow.

Developing the Next Generation of Medicines

We continually invest in innovation to address unmet need for patients across a variety of disease areas.

Since our inception as an independent company in January 2013, AbbVie has invested over $55 billion in research and development. We continue to conduct clinical trials in important disease areas with unmet needs, including lupus, Parkinson’s disease, cancer and major depressive disorder. In all, more than 1.6 billion people have the potential to be treated by therapies we are researching, including nearly 280 million people in the U.S. In 2022 alone, AbbVie’s adjusted investment was $7.1 billion.1

In addition to undertaking significant internal research efforts, we also invest in new, promising innovations that are discovered by scientists outside of AbbVie.

1 2022 adjusted investment reflects adjusted non-GAAP R&D expense and acquired IPR&D and milestones expense.
We contribute to organizations that facilitate scientific knowledge-sharing and increase access for patients around the world.

AbbVie contributes to the World Intellectual Property Organization’s Patent Information Initiative for Medicines database. This database provides patent information on medicines from the WHO Essential Medicines list, including medicines for HIV/AIDS, cardiovascular disease, diabetes, hepatitis C (HCV), cancers and respiratory conditions.

AbbVie has also entered into licensing agreements with the Medicines Patent Pool (MPP) to increase access to critical medicines for patients in LMICs. Our MPP agreements span nearly 100 countries for Mavyret, an AbbVie medicine used to treat chronic HCV. For Aluvia FD, an antiviral medicine used to treat HIV, we have MPP agreements in place that cover over 100 countries of which more than 65 are classified as middle-income nations.

We are committed to bringing innovation in neglected diseases and areas of high unmet need.

AbbVie’s Executive Council on Neglected Diseases coordinates across the company to contribute innovative technologies, diverse compounds for screening and scientific expertise to partners to help address neglected tropical diseases.

At AbbVie, more than 400 scientists have given over 195,000 hours of their time toward advancing research and potential medications to treat neglected diseases that disproportionately affect LMICs, including malaria, tuberculosis and river blindness (onchocerciasis).

Ultimately, our commitment to science is a commitment to better our society.

For AbbVie, making a difference begins with our work to discover and develop transformative medicines. Our efforts to make our medicines accessible for people and to support patients throughout their treatment journey are just as critical to AbbVie’s patient impact. From lab to patient, we are committed to pursuing collaboration with our communities, patients and customers, employees, policymakers and the public to align our collective capabilities to improve lives today and address the biggest health challenges of tomorrow.